Short Interest in PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Decreases By 39.6%

Key Points

• PureTech Health PLC's short interest decreased by 39.6% in July, falling from 5,300 shares to 3,200 shares.
• The company's stock is currently trading around $19.05, showing a 50-day moving average of $18.25 and a 1-year high of $25.00.
• Several hedge funds have recently increased their investments in PureTech Health, with a notable 39.2% increase in holdings by Pentwater Capital Management LP during the first quarter.

PureTech Health PLC Sponsored ADR (NASDAQ:PRTC - Get Free Report) was the recipient of a significant decline in short interest in the month of July. As of July 31st, there was short interest totaling 3,200 shares, adeclineof39.6% from the July 15th total of 5,300 shares. Based on an average trading volume of 3,500 shares, the days-to-cover ratio is presently 0.9 days. Currently,0.0% of the company's shares are sold short. Currently,0.0% of the company's shares are sold short. Based on an average trading volume of 3,500 shares, the days-to-cover ratio is presently 0.9 days.

Institutional Investors Weigh In On PureTech Health

A number of large investors have recently modified their holdings of PRTC. Persistent Asset Partners Ltd bought a new stake in shares of PureTech Health during the 2nd quarter valued at about $29,000. Diadema Partners LP bought a new stake in shares of PureTech Health during the 2nd quarter valued at about $126,000. Pentwater Capital Management LP boosted its stake in shares of PureTech Health by 39.2% during the 1st quarter. Pentwater Capital Management LP now owns 33,560 shares of the company's stock valued at $664,000 after purchasing an additional 9,449 shares in the last quarter. Finally, Millennium Management LLC bought a new stake in shares of PureTech Health during the 4th quarter valued at about $823,000. Institutional investors own 0.04% of the company's stock.

PureTech Health Price Performance

Shares of PRTC stock traded up $0.31 during mid-day trading on Friday, reaching $18.71. The stock had a trading volume of 1,806 shares, compared to its average volume of 2,866. The stock's 50-day moving average price is $18.21 and its two-hundred day moving average price is $17.89. PureTech Health has a 52-week low of $13.30 and a 52-week high of $25.00.

About PureTech Health

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.